CERRITOS, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology practices in the country, today announced that Dr. Daniel Virnich, TOI’s Chief Executive Officer, will participate in the “Defining the Next Chapter in Value-Based Care” panel at the Leerink Healthcare Transformation Summit in Montecito at 8:30am ET on May 16, 2024.
Key Points:
- CERRITOS, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology practices in the country, today announced that Dr. Daniel Virnich, TOI’s Chief Executive Officer, will participate in the “Defining the Next Chapter in Value-Based Care” panel at the Leerink Healthcare Transformation Summit in Montecito at 8:30am ET on May 16, 2024.
CERRITOS, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2024 financial results after the market close on Tuesday, May 14, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).
Key Points:
- CERRITOS, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2024 financial results after the market close on Tuesday, May 14, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).
- The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562.
- A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671.
- The replay will be available until Tuesday, May 21, 2024.
CERRITOS, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) is pleased to announce the appointment of Jordan McInerney as the new Chief Development Officer (CDO), effective April 1, 2024. In this role, Mr. McInerney will spearhead growth initiatives for The Oncology Institute across diverse markets, including cultivating new partnerships with payors, driving M&A processes for acquisition targets, and establishing MSO platforms to deliver value-based oncology care nationwide.
Key Points:
- CERRITOS, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) is pleased to announce the appointment of Jordan McInerney as the new Chief Development Officer (CDO), effective April 1, 2024.
- Bringing over 15 years of healthcare leadership, McInerney most recently served as the Chief Operations Officer of HOPCo Network Solutions, a subsidiary of Healthcare Outcomes Performance Co. (HOPCo).
- "We are delighted to welcome Jordan McInerney to The Oncology Institute as our new Chief Development Officer," stated Dr. Daniel Virnich, Chief Executive Officer at The Oncology Institute.
- "I am deeply honored to join The Oncology Institute and to spearhead development efforts for such a remarkable organization dedicated to advancing value-based cancer care," expressed McInerney.
Commencing July 1, 2024, TOI will offer its cancer care services to patients affiliated with Healthly’s medical groups and associated physicians across the region.
Key Points:
- Commencing July 1, 2024, TOI will offer its cancer care services to patients affiliated with Healthly’s medical groups and associated physicians across the region.
- Leveraging TOI’s extensive network of oncology clinics and providers, this partnership aims to deliver convenient and comprehensive cancer care services to patients within the Healthly network.
- “Navigating cancer is a multifaceted challenge, often representing one of the most trying periods in a patient’s life.
- Through this strategic partnership, we aim to offer innovative care pathways, including access to clinical trials, to enhance patient access to cutting-edge drugs and treatments at reduced costs.”
Retrieved on:
Wednesday, March 27, 2024
Consolidated revenue for Q4 2023 was $86 million, an increase of 20.1% compared to Q4 2022, and a 4.6% increase compared to Q3 2023.
Key Points:
- Consolidated revenue for Q4 2023 was $86 million, an increase of 20.1% compared to Q4 2022, and a 4.6% increase compared to Q3 2023.
- Gross profit in Q4 2023 was $14 million, a decrease of 8.0% compared to Q4 2022.
- Gross profit is calculated by subtracting direct costs of patient services, dispensary, and clinical trials and other from consolidated revenues.
- TOI will host a conference call on Wednesday, March 27, 2024 at 5:00 p.m. (Eastern Time) to discuss fourth quarter and full year results and management’s outlook for future financial and operational performance.
CERRITOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), a leading value-based oncology group, and MaxHealth, an innovative leader in value-based primary care, have announced a comprehensive new agreement.
Key Points:
- CERRITOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), a leading value-based oncology group, and MaxHealth, an innovative leader in value-based primary care, have announced a comprehensive new agreement.
- Under this full-risk arrangement, TOI will assume clinical and financial responsibility for all oncology care provided to patients in Pinellas, Hillsborough, Polk, Broward, and Miami-Dade Counties.
- This innovative payment model aligns seamlessly with MaxHealth's existing value-based care agreements with large managed care organizations.
- “We are excited to strengthen our partnership with MaxHealth, a distinguished primary care organization,” expressed Dr. Daniel Virnich, TOI’s Chief Executive Officer.
The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562.
Key Points:
- The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562.
- A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671.
- The passcode for the live call and the replay is 13744947.
- The replay will be available until Wednesday, April 3, 2024.
Retrieved on:
Tuesday, February 27, 2024
CERRITOS, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology practices in the country, today announced that Dr. Daniel Virnich, TOI’s Chief Executive Officer, will participate at the following investor conferences:
Key Points:
- CERRITOS, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology practices in the country, today announced that Dr. Daniel Virnich, TOI’s Chief Executive Officer, will participate at the following investor conferences:
Interested investors and other parties may listen to simultaneous webcasts of the presentations by logging onto the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/ .
- The online replay will be available for a limited time shortly following the call.
Retrieved on:
Tuesday, February 20, 2024
SAN FRANCISCO and LAS VEGAS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Today, The Oncology Institute (TOI), one of the largest value-based oncology practices in the country, announced its partnership with Carrum Health.
Key Points:
- SAN FRANCISCO and LAS VEGAS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Today, The Oncology Institute (TOI), one of the largest value-based oncology practices in the country, announced its partnership with Carrum Health.
- Through employers, Carrum Health will offer patients a comprehensive bundled package for breast cancer care, covering two years treatment, including chemotherapy, office visits, and symptom management through TOI.
- Dr. Daniel Virnich, CEO of The Oncology Institute (TOI), shared his commitment to this venture, stating, “We are deeply committed to providing high quality oncology care to breast cancer patients, in partnership with Carrum Health.
- "The Oncology Institute offers high quality, compassionate care for individuals navigating the challenges of cancer.
Retrieved on:
Thursday, January 25, 2024
WellBe now offers The Oncology Institute’s High-Value Cancer Care Program to eligible patients in Illinois and Ohio.
Key Points:
- WellBe now offers The Oncology Institute’s High-Value Cancer Care Program to eligible patients in Illinois and Ohio.
- As part of this program, TOI provides care management and supportive care services customized to the needs of the individual patient with active cancer diagnoses.
- “At WellBe, we partner with health plans to care for their most complex members and bring customized care to their homes,” shared Dr. Iyad Houshan, Chief Medical Officer of WellBe Senior Medical.
- “WellBe’s mission to provide tailored care to the frailest seniors aligns with TOI’s goals in cancer care.
